Recent Company News

• 09:07 PM ET Jul 30, 2025
  

  Takeda Pharmaceutical trading (1.3%) after reporting mixed results with revenue affected by expiration of Vyvanse patent (¥4236.0000, -60)

• 07:14 PM ET Jul 30, 2025
  

  Japan post-close earnings highlights:

• 02:41 AM ET Jul 30, 2025
  

  StreetAccount Metrics Recap - Takeda Pharmaceutical Q1 Earnings (¥4296.0000, 0)

• 02:36 AM ET Jul 30, 2025
  

  Takeda Pharmaceutical reports Q1 net income attributable ¥124.24B vs FactSet ¥87.75B [4 est, ¥55.50-129.10B] (¥4296.0000, 0)

• 08:01 AM ET Jul 21, 2025
  

  FDA grants 510(k) clearance for Takeda's HyHub, HyHub Duo

• 08:04 AM ET Jul 17, 2025
  

  Keros Therapeutics announces first patient dosed in phase 3 RENEW trial of elritercept in MDS ($14.49, 0.00)

• 09:18 AM ET Jul 14, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 03:08 AM ET Jul 14, 2025
  

  Takeda Pharmaceutical's TAK-861 meets all primary and secondary endpoints in two phase 3 studies in narcolepsy type 1 (¥4361.0000, 0)

• 03:04 AM ET Jul 02, 2025
  

  JCR Pharmaceuticals enrolls participants in JR-141 global phase III clinical trial (¥503.0000, 0)

• 10:11 AM ET Jun 30, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (130 total)